20Mar 2017


  • Department of Pharmacy, University of Asia Pacific, Dhaka-1215, Bangladesh.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

In the present study, an attempt was made to design and evaluate bilayer gastroretentive drug delivery system exhibiting a combination of an immediate release layer and a sustained release mucoadhesive layer as second layer to prolong residence time in stomach using Metformin HCl as a model drug to reduce frequency of administration and to overcome bioavailability problems. A total of 5 formulations of bilayer tablets containing the drug were prepared by direct compression method using 5 different mucoadhesive polymers in 5 different formulations (F1-F5) respectively to impart mucoadhesion. Formulated bilayer tablets were evaluated by different parameters such as; ex vivo mucoadhesion strength, ex vivo mucoadhesion time, In vitro drug release study. In vitro drug release data were fitted to various kinetic models (Zero order, 1st order, Higuchi model, Korsmeyer- Peppas model). Upon R2 value analysis it was observed that release from F1, F3, F5 followed Higuchi model and F2, F5 followed Korsmeyer- Peppas kinetic model. Mechanism of drug release was found to be Fickian diffusion (value of n <0.45). F4 with Na CMC was found to be more promising in ex vivo mucoadhesion study showing residence time of 4.08 hrs. This study concludes that formulated bilayer tablets were satisfactory in providing prompt release from 1st layer then maintained sustained release effect with promising mucoadhesion behavior in stomach.

  1. Boddupalli,M., Mohammed, Z.N.K., Nath, R.A. and Banji, D. (2010): Mucoadhesive drug delivery system: an overview. J. Adv. Pharm. Technol. Res., 1(4): 381?387.
  2. Smart, J.D. (2005): The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliver. Rev., 57: 1556?1568.
  3. H?gerstrom, H. and Edsman, K. (2003): Limitations of the rheological mucoadhesion method: the effect of the choice of conditions and the rheological synergism parameter. Eur. J. Pharm. Sci., 18: 349?357.
  4. Kadhe, G. and Arasan, R.E. (2002): Advances in drug delivery of oral hypoglycemic agents. Curr. Sci., 83(12): 1539-1543.
  5. Desvergne, B. and Wahli, W. (1999): Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 20: 649-668.
  6. Berger, J. and Moller, D.E. (2002): The mechanisms of action of PPARs. Annu. Rev. Med., 53: 409-435.
  7. Chawla, A., Repa, J.J. and Evans, R.M. (2001): Nuclear receptors and lipid physiology: opening the X-files. Science, 294: 1866-1870.
  8. Chinetti, G., Fruchart, J.C. and Staels, B. (2000): Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 49: 497-505.
  9. Willson, T.M., Lambert, M.H. and Kliewer, S.A. (2001): Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem., 70: 341-367.
  10. Singh, P.K., Shukla, V.K., Easwari, T.S., Kumar, S., Chaudhary, R. and Saraswat, S. (2012): Formulation development and evaluation of mucoadhesive oral dosage form containing clarithromycin using different mucoadhesive polymers. Int. J. Pharm. Sci.Health Care., 2(2): 166.
  11. Umarji, B., Patil, R., Birajdar, R., Mysore, S., Bilagi, S. and Audurti, D. (2012): Formulation and in vitro evaluation of mucoadhesivebuccal tablets of furosemide. WJPPS, 1(3): 1041-1063.

[Sabnin Shair, Nafisa Nowal Rafa, Abu Sufian, A. H. M. Nazmul Hasan and Asaduzzaman. (2017); FORMULATION DEVELOPMENT OF MUCOADHESIVE BILAYER TABLET WITH METFORMIN HYDROCHLORIDE. Int. J. of Adv. Res. 5 (3). 8-14] (ISSN 2320-5407). www.journalijar.com

Md. Asaduzzaman
Department of Pharmacy, University of Asia Pacific, Dhaka-1215, Bangladesh


Article DOI: 10.21474/IJAR01/3476       DOI URL: http://dx.doi.org/10.21474/IJAR01/3476

Share this article